22.03.2012 - Two pharma majors have announced on BIO-Europe Spring (Amsterdam) to back the launch of a €150m life science investment fund, managed by Index Ventures.
The investment backed by Johnson&Johnson and GlaxoSmithKline represents a new pharmaceutical-VC partnership model intended to propel early stage pre-competitive innovation. The fund includes investments from several of Index’s largest existing limited partners, which can capitalise on the shared expertise of GSK and J&J through their participation in the fund’s scientific advisory board. “The endeavor we are taking to discover new drugs is enormous. It’s key for us to reach out to any new ideas anywhere in the world,” said Moncef Slaoui, Chairman R&D, GSK. “We need to capture the diversity of ideas and talent.” With the investment into early biotech research pharma companies want to fill the productivity gap in their own pipelines. According to figures published by Eli Lilly advisor Bernhard Munos in Forbes, pharma companies currently have to invest between US$4bn to US$11bn to bring a new entity to the market.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.